Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 269 full-time employees. The company went IPO on 2017-06-14. The firm is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The firm's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.

Industry: Pharmaceutical Preparations Peers: Aligos Therapeutics Inc Ambrx Biopharma Cayman, Inc. Applied Molecular Transport Inc. Beyondspring Inc Perspective Therapeutics Inc PhaseBio Pharmaceuticals Inc Sellas Life Sciences Group Inc Oncternal Therapeutics, Inc. Rubius Therapeutics, Inc.